Table 6 Risk of ovarian cancer death and CA-125 serum concentration changes 3 and 6 months after therapy in subgroups of patients. NACT-Neoadjuvant chemotherapy
Subgroups of patients | Risk of ovarian cancer death - HR (p) | |||||
|---|---|---|---|---|---|---|
CA-125 changes 3 months after therapy [U/ml] | CA-125 changes 6 months after therapy [U/ml] | |||||
< 0 | 0–5 | > 5 | < 0 | 0–5 | > 5 | |
FIGO 1&2 (n = 52) | 1.00 | 2.76 (p = 0.2065) | 5.65 (p = 0.1636) | 1.00 | 1.76 (p = 0.4893) | 3.58 (p = 0.2080) |
FIGO 3&4 (n = 116) | 1.00 | 1.45 (p = 0.3157) | 3.9 (p = 0.0121) | 1.00 | 0.80 (p = 0.5824) | 3.11 (p = 0.0037) |
Grade 2&3 (n = 152) | 1.00 | 1.90 (p = 0.0617) | 3.91 (p = 0.006) | 1.00 | 0.94 (p = 0.8647) | 3.24 (p = 0.0015) |
Serous (n = 124) | 1.00 | 1.59 (p = 0.191) | 4.4 (p = 0.0055) | 1.00 | 0.91 (p = 0.8035) | 2.79 (p = 0.0092) |
NACT (n = 26) | 1.00 | 5.14 (p = 0.1322) | 7951 (p = 0.9994) | 1.00 | 1.07 (p = 0.9291) | 2.14 (p = 0.3347) |
Bevacizumab (n = 32) | 1.00 | 3.88 (p = 0.0915) | – | 1.00 | 0.81 (p = 0.7677) | 42.16 (p = 0.0025) |
Optimal cytoreduction (< 1 cm) (n = 145) | 1.00 | 2.21 (p = 0.128) | 4.05 (p = 0.0958) | 1.00 | 1.09 (p = 0.8648) | 3.15 (p = 0.0405) |